CBS 2019
CBSMD教育中心
中 文

肺动脉高压

Abstract

Recommended Article

Increased pulmonary serotonin transporter in patients with chronic obstructive pulmonary disease who developed pulmonary hypertension Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study A Case of Pulmonary Hypertension Associated with Idiopathic Hypereosinophilic Syndrome Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry Pulmonary Artery Denervation Using Catheter based Ultrasonic Energy Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension The right ventricle in pulmonary hypertension

Original Research2022 Apr, 79 (15) 1477–1488

JOURNAL:J Am Coll Cardiol. Article Link

Percutaneous Pulmonary Angioplasty for Patients With Takayasu Arteritis and Pulmonary Hypertension

Y-P Zhou , Y-P Wei , Y-J Yang et al.

ABSTRACT

BACKGROUND - Percutaneous transluminal pulmonary angioplasty (PTPA) is a treatment modality for chronic thromboembolic pulmonary hypertension, but whether it can be applied to Takayasu arteritisassociated pulmonary hypertension (TA-PH), another chronic obstructive pulmonary vascular disease, remains unclear.

 

OBJECTIVES - This study sought to investigate the efficacy and safety of PTPA for TA-PH.

 

METHODS - Between January 1, 2016, and December 31, 2019, a total of 50 patients with TA-PH who completed the PTPA procedure (the PTPA group) and 21 patients who refused the PTPA procedure (the non-PTPA group) were prospectively enrolled in this cohort study. The primary outcome was all-cause mortality. The safety outcomes included PTPA procedure-related complications.

 

RESULTS - Baseline characteristics and medical therapies were similar between the PTPA group and the non-PTPA group. During a mean follow-up time of 37 ± 14 months, deaths occurred in 3 patients (6.0%) in the PTPA group and 6 patients (28.6%) in the non-PTPA group, contributing to the 3-year survival rate of 93.7% in the PTPA group and 76.2% in the non-PTPA group (P = 0.0096 for log-rank test). The Cox regression model showed that PTPA was associated with a significantly reduced hazard of all-cause mortality in TA-PH patients (HR: 0.18; 95% CI: 0.05-0.73; P = 0.017). No periprocedural death occurred. Severe complications requiring noninvasive positive pressure ventilation occurred in only 1 of 150 total sessions (0.7%).

 

CONCLUSIONS - PTPA tended to be associated with a reduced risk of all-cause mortality with acceptable safety profiles and seemed to be a promising therapeutic option for TA-PH patients.